Our objective was to evaluate the safety and efficacy of clomiphene citrate (CC) in infertile and hypoandrogenic men through a retrospective study between September 2013 and May 2014. We identified 47 men between 18 and 55 years placed on 50 mg CC every other day. We evaluated the effect of CC on testosterone after 2 weeks, rates of adverse effects and predictors of CC response. Mean baseline testosterone, bioavailable testosterone and estradiol were 246.8 ng dl − 1 , 125.5 ng dl − 1 and 20.8 pg dl − 1 , respectively. At 2 weeks, mean testosterone, bioavailable testosterone and estradiol increased to 527.6 ng dl − 1 , 281.8 ng dl − 1 and 32.0 pg dl − 1 (all P o0.001). Two patients at 2 weeks and one patient at 3 months had a paradoxical decrease in testosterone. Mean total motile count (TMC) and concentration increased from 59.7 million (s.e.m.: 16.5) and 50.7 millions ml − 1 (s.e.m.: 11.1) at baseline to 90.9 million (s.e.m.: 25.9) and 72.5 millions ml − 1 (s.e.m.: 17.5), respectively, at 3 months, although this was nonsignificant (P = 0.09, 0.09). No patient on CC experienced a paradoxical decrease in TMC or sperm concentration. On age-adjusted regression analysis, age, BMI, longitudinal testis axis, baseline follicle-stimulating hormone, LH and estradiol did not correlate with improvement in bioavailable testosterone at 2 weeks. CC improves testosterone and may improve semen parameters, although a small percentage of men may not demonstrate improvement in testosterone.
INTRODUCTION
Clomiphene citrate (CC), originally approved for the treatment of ovulatory dysfunction in women, has been used for several conditions affecting men. It is used for the treatment of male infertility associated with hypoandrogenism, or low serum testosterone. [1] [2] [3] CC is a selective estrogen receptor modulator (SERM) that alters the function of the hypothalamic-pituitary-gondal (HPG) axis. 4, 5 It binds estrogen receptors in the hypothalamus and inhibits normal negative feedback exerted by estrogen on the hypothalamus and pituitary gland. This leads to increased production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), stimulating Leydig cells in the testis to produce testosterone. The increase in endogenous testosterone, especially within the testes, stimulates spermatogenesis. Most adverse events associated with CC are mild and dose related. Although uncommon, adverse effects include headache, dizziness, blurred vision, nausea, vomiting, gynecomastia, weight gain and hypertension. 4, 6 Despite the established use of CC in men, usage in males is off-label and not approved by the Food and Drug Administration for male subfertility or hypoandrogenism. 6, 7 Many studies have established the efficacy of CC for male subfertility or hypoandrogenism with improved serum testosterone levels and/or improved semen parameters. 2, 5, 8, 9 However, several case series and observational studies have also demonstrated the possibility of an adverse or paradoxical response in testosterone levels and/ or semen parameters, seen in 5-10% of men. 5, 9, 10 Additionally, cases of spontaneous non-bacterial pyospermia and azoospermia have been reported in men on CC. 11, 12 Currently, there are limited data regarding predictors of an adverse or paradoxical testosterone response among all men treated with CC.
The purpose of our study was to evaluate the safety and efficacy of CC in hypoandrogenic men and identify baseline predictors of change in bioavailable testosterone levels. We hypothesize that baseline FSH, LH and longitudinal testis axis may identify changes in bioavailable testosterone with CC treatment.
MATERIALS AND METHODS
We completed a retrospective cross-sectional study at the Andrology/Men's Health clinic of the University of Utah following institutional review board approval. Men between the ages of 18 and 55 years presenting between September 2013 and May 2014 were identified. Those men presenting for evaluation of hypoandrogenism and/or subfertility and subsequently placed on CC 50 mg every other day were selected. Regardless of presentation, included patients had a serum total testosterone of o300 ng dl − 1 and/or bioavailable testosterone o155 ng dl − 1 before treatment. CC dosage was increased to 50 mg every day in patients with suboptimal response in serum testosterone levels (o50 ng dl − 1 ) after 2 weeks of treatment. Patients with previous exogenous testosterone, tamoxifen, human chorionic gonadotropin (hCG) or anastrozole use were excluded.
Patient history (age, body mass index (BMI), history of non-obstructive azoospermia) and genitourinary physical exam features (longitudinal testis axis and varicocele status) were collected. The responses to the Androgen Deficiency in Aging Males (ADAM) and Sexual Health Inventory for Men (SHIM) scores were also recorded. Three or more positive ADAM responses suggested hypoandrogenism and an SHIM score of ⩽ 21 suggested sexual dysfunction. [13] [14] [15] FSH, LH, sex-hormone-binding globulin (SHBG), estradiol, total testosterone and albumin were collected at baseline and after 2 weeks of treatment. All specimens were collected between 0600 and 1000 hours. FSH, LH, sex-hormone-binding globulin and total testosterone were analyzed by quantitative electrochemiluminescent immunoassay. 16 Estradiol levels were determined by quantitative high-performance liquid chromatography-tandem mass spectrometry. 16 Bioavailable testosterone was calculated from total testosterone, sex-hormone-binding globulin and serum albumin. 17 Semen analysis data (ejaculate volume, total motile count, sperm concentration, percentage progressively motile and percentage of normal morphology) was also collected at baseline and after 3 months of CC treatment. A high-volume reference Andrology laboratory performed semen analysis in accordance with the 2010 World Health Organization manual for examination and processing of human semen. 18 Our primary outcome was change in bioavailable testosterone and total testosterone levels after 2 weeks on CC. We also evaluated the association of baseline demographics and hormone levels with expected or unexpected response to CC and recorded all reported adverse effects.
Continuous variables were summarized by mean, s.d., median and interquartile range (IQR). A paired-samples t-test was used to compare hormone levels and semen parameters at 2 weeks and 3 months with baseline, respectively. Rates of adverse events were also tabulated. An ageadjusted regression analysis was designed to determine the relationship between continuous variables and change in bioavailable testosterone. All statistical analyses results were generated using the SAS software, version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Fifty-seven men placed on CC were identified; however, 10 men were excluded because of incomplete baseline labs. Thus, a total of 47 men were included in this analysis. Mean age and BMI were 34.5 and 30.2 years, respectively. Twenty-six men (55%) had 3 or more positive ADAM responses and 13 men (28%) had SHIM scores o 21. Median follow-up time was 3.0 months (IQR: 2.3-3.7).
Effect of CC on serum hormone levels
The mean baseline values and changes in hormone levels after 2 weeks of treatment with CC are shown in Table 1 . There was a statistically significant improvement in both total testosterone (mean absolute improvement of 280.8 ng dl − 1 , P o 0.001) and bioavailable testosterone (155.3 ng dl − 1 , P o0.001).
Effect of CC on semen analysis parameters
The effect of CC on semen analysis parameters after 3 months of treatment is shown in Table 2 . Mean ejaculate volume, percentage progressively motile and percentage of normal morphology were similar at 3 months vs baseline. However, mean total motile count and concentration increased to 90.9 and 72.5 millions ml − 1 at 3 months from 59.7 and 50.7 millions ml − 1 at baseline, respectively, although these findings were not significant (P = 0.09, 0.09).
Correlation of baseline demographics and hormones levels with improvement in bioavailable testosterone on CC On unadjusted and age-adjusted regression analysis, age, BMI, longitudinal testis axis, baseline FSH, LH and estradiol did not significantly correlate with improvement in bioavailable testosterone at 2 weeks (Table 3 ). Additionally, three or more positive ADAM responses, SHIM score o 21 and varicocele presence at baseline was not associated with bioavailable testosterone levels following 2 weeks of CC (P = 0.85, 0.68, 0.72, respectively).
Adverse effects of CC Adverse effects were reported in five (11%) of patients. Two patients had a paradoxical decrease in total testosterone at 2 weeks and were switched to hCG (absolute decrease of 11.0 and 57.3 ng dl − 1 ). Both patients had an adequate response to hCG treatment after 2 weeks, with an increase of 655 and 82 ng dl − 1 in total testosterone, respectively, when compared with their postclomiphene values. An additional two patients discontinued CC at 3 months: one because of increased fatigue and mood symptoms and one who experienced a delayed decline in total testosterone compared with total testosterone at 2 weeks (absolute decrease of 222.0 ng dl − 1 ). No patients experienced a paradoxical decrease in total motile count or concentration while on CC after 3 months.
DISCUSSION
Our study shows that CC is well tolerated and effective for improvement of testosterone in hypoandrogenic and subfertile men. 
Clomiphene citrate in men
We observed a significant improvement in testosterone and bioavailable testosterone following 2 weeks of treatment. Additionally, we observed improvements in total motile count and sperm concentration, although they were not significant in our statistical analysis. Adverse effects were rare and three patients experienced a paradoxical decrease in serum testosterone on treatment. We were unable to identify any baseline demographic characteristics, which would predict serum bioavailable testosterone response to CC among hypoandrogenic and subfertile men. CC is commonly used for the treatment of male subfertility and as an alternative to testosterone supplementation for hypoandrogenism in reproductive aged men. It is generally well tolerated and adverse effects reported in our cohort (fatigue and mood symptoms) are known side effects detailed in the prescribing information. 6 Information on adverse effects in efficacy studies of CC is variable. 8, 19 Only mild symptoms such as headache, dizziness or visual disturbances have been reported among CC efficacy studies. 20, 21 However, a small percentage of men may develop a paradoxical decrease in testosterone or negative impact on semen parameters. [2] [3] [4] Reports of paradoxical response to CC therapy are limited to small case series that showed either a decrease in testosterone or an adverse effect on sperm morphology. A small case series reported three men who developed azoospermia during CC therapy, who subsequently had return of sperm to their ejaculate after CC cessation. 12 Additionally, Ribeiro and Abucham 22 reported a series of nine hypogonadotropic hypogonadal patients treated with CC who experienced a decline in testosterone levels. In our study, only three (6%) patients experience a paradoxical decrease in testosterone, while on CC, two patients at 2 weeks and one patient at 3 months of treatment. Additionally, no patients in our study experienced a paradoxical decrease in total motile count or concentration after 3 months of CC treatment.
The overall response rates (improvement in testosterone) to CC in men ranged from 62 to 74%. 23, 24 The characteristics and predictors of a positive response to CC are limited. 10 Several demographic factors such as age and BMI and baseline hormone values including FSH and LH, as well as testicular size, have been proposed as predictors of CC response among hypoandrogenic men. Previously, Guay et al. 24 found that older age and multiple chronic medical conditions were associated with a poor improvement in serum testosterone among 178 hypoandrogenic men treated with CC. In a recent study by Mazzola et al., 23 nearly 40% of hypoandrogenic men on CC were non-responders (response defined as 4200 ng dl − 1 improvement in total testosterone levels after 6 months of CC treatment). On multivariate analysis, testicular volume and baseline LH level was predictive of a positive response in this cohort of hypoandrogenic men. To our knowledge, this study is the first to assess predictors of CC response in hypoandrogenic and subfertile men. We did not find an association between age, BMI, FSH, LH, estradiol or testicular axis and changes in bioavailable testosterone while on CC in a cohort of hypoandrogenic and subfertile men.
Genetic polymorphisms in cytochrome P450 D26 may also offer a biologic rationale for variable responses of CC. 25 Cytochrome P450 D26 is an enzyme that metabolizes CC to its active forms (E)-4-hydroxyclomiphene and (E)-4-hydroxy-N-desethylclomiphene. Individuals with specific non-functional alleles for P450 D26 have 8-to 12-fold lower concentrations of these active metabolites. 25 Pharmacogenetic and pharmacodynamic studies for tamoxifen, another selective estrogen receptor modulator similar to CC commonly studied in breast cancer, have proposed that singlenucleotide polymorphisms may determine the variability in drug sensitivity. 26 Future pharmacogenetic studies of CC among hypoandrogenic and subfertile men are also necessary.
There are several limitations to our study. Our results are limited by the small sample size and limited follow-up. Additionally, we were unable to capture subjective changes on the ADAM and SHIM questionnaires after CC treatment as these questionnaires were only administered at baseline. Single total testosterone measurements at baseline and at 2 weeks posttreatment and calculated bioavailable testosterone rather than direct measurement are also known limitations. There is an 18-28% intraindividual variability in 50% of patients with multiple serum testosterone measurements, which impacts analysis of our results. 27 Calculated bioavailable testosterone is still helpful and more effective in assessing androgenic status compared with total testosterone alone. 28 Finally, the lack of age-matched controls in our study limits appropriate interpretations of the results. A randomized, prospective trial of CC for hypoandrogenic men with subfertility is necessary to evaluate predictors of a positive response. This study must also report side effects associated with CC treatment and rates of paradoxical changes in testosterone or semen parameters.
CONCLUSION
CC is a viable treatment consideration for hypoandrogenism in subfertile men that improves testosterone and may improve total motile count and sperm concentration. A small but significant portion of men on CC may not demonstrate improvement in testosterone or decrease in testosterone levels. Age, BMI, FSH, LH, estradiol and longitudinal testis axis were not predictive of change in bioavailable testosterone in our study.
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